Feedback
HLA-B27
0095840
Ordering Recommendation

May assist in the diagnosis of ankylosing spondylitis, juvenile rheumatoid arthritis, and Reiter's syndrome. This test is not diagnostic for these disorders and should be correlated with other clinical signs and symptoms.

Mnemonic
HLAB27
Methodology
Qualitative Flow Cytometry
Performed
Sun-Sat
Reported
1-2 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
 
Collect
Lavender Hemogard (EDTA), pink Hemogard (K2EDTA), or green Hemogard (sodium or lithium heparin). Hemogard tubes are preferred for laboratory safety. 
Specimen Preparation
Transport 4 mL whole blood. (Min: 0.5 mL) 
Storage/Transport Temperature
CRITICAL ROOM TEMPERATURE. 
Unacceptable Conditions
Frozen or refrigerated specimens. Specimens older than 72 hours. Clotted or hemolyzed specimens.
New York State Clients: Frozen or refrigerated specimens. Heparin specimens older than 48 hours or EDTA specimens older than 30 hours. Clotted or hemolyzed specimens. 
Remarks
Specimens must be analyzed within 72 hours of collection.
New York State Clients: EDTA specimens must be analyzed within 30 hours of collection. Heparin specimens must be analyzed within 48 hours of collection. 
Stability
Ambient: 72 hours; Refrigerated: Unacceptable; Frozen: Unacceptable
New York State Clients: Ambient: 30 hours in EDTA, 48 hours in heparin; Refrigerated: Unacceptable; Frozen: Unacceptable 
Reference Interval
Negative
Interpretive Data
HLA-B27 is a serologically-defined allele of the human HLA-B locus. The presence of the HLA-B27 antigen is strongly associated with ankylosing spondylitis and related disorders.

The performance characteristics of this test were determined by ARUP Laboratories, Inc.

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
Indeterminate Results: The Anti-HLA-B27 antibody (clone GS145.2) used in the HLA-B27 assay can cross-react with some other HLA-B locus antigens, creating false-positive results for HLA-B27 expression. Therefore, results falling within the established indeterminate zone will include a recommendation of genotype testing to confirm positive HLA-B27 expression. Order Ankylosing Spondylitis HLA-B27 Genotyping, (ARUP test code 0050392).
Components
Component Test Code*Component Chart NameLOINC
0095030HLA-B2726028-1
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Ankylosing Spondylitis
  • HLA Antigen B27
  • HLA-B27 Antigen